Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: Post-hoc analyses from the GO-AFTER study

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1811-1818

  Smolen, Josef S ^a   Kay, Jonathan ^b   Matteson, Eric L ^c   Landewé, Robert ^d   Hsia, Elizabeth C ^e,f   Xu, Stephen ^e   Zhou, Yiying ^e   Doyle, Mittie K ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; GOLIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881180565     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203435     Document Type: Article

References (42)

1. Hetland ML, Christensen IJ, Tarp U, et al.; on behalf of All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Singh JA, Furst D, Bharat A. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
4. Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009;11:R163.
5. Erickson AR, Mikuls TR. Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 2007;9:416-20.
6. Gomez-Reino JJ, Carmona L; and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
7. Hyrich KL, Lunt M, Watson KD, et al. for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
8. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009;61:107-17.
9. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004;22(Suppl 35):S115-21.
10. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
11. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007;66:893-9.
12. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
13. Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-32.
14. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
15. Finckh A, Ciurea A, Brulhart L, et al.; on behalf of the physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
16. Cohen SB, Emery P, Greenwald MW, et al. for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
17. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
18. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-23.
19. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54.
20. Smolen JS, Kay J, Doyle MK, et al., for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
21. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
22. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009; (4): CD007848.
23. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8.
24. Finckh A, Ciurea A, Brulhart L, et al., on behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid Arthritis.. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
25. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
26. Prevoo M L L, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. van Riel P L CM, van Gestel AM, Scott DL; on behalf of The EULAR Standing Committee for International Clinical Studies including Therapeutic Trials-ESCISIT. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications B. V., 2000:40.
28. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
29. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
30. Smolen JS, Kay J, Landewé R B M, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671-9.
31. Breedveld FC, Weisman MH, Kavanaugh AF, et al. for the PREMIER Investigators. the PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
32. Klareskog L, van der Heijde D, de Jager JP, et al. for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
33. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
34. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 2012;51(Suppl 5):22-30.
35. Kremer JM, Tony H, Tak PP, et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006;65(Suppl II):326 (Abstract FRI0133)
36. Poster session FRI0133 presented at the 7th Annual European Congress of Rheumatology (EULAR 2006), Amsterdam, 21-24 June 2006.
37. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-14.
38. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
39. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
40. Enbrel (Etanercept) Summary of Product Characteristics. European Medicines Agency. http://www.medicines.org.uk/emc/medicine/3343/SPC/ (accessed Jan 2013).
41. Humira (Adalimumab) Summary of Product Characteristics. European Medicines Agency. http://www.medicines.org.uk/emc/medicine/21201/SPC/ (accessed Jan 2013).
42. Remicade (Infliximab) Summary of Product Characteristics. European Medicines Agency. http://www.medicines.org.uk/emc/medicine/3236/SPC/ (accessed Jan 2013).